MA38227A1 - Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ?-lactamase - Google Patents
Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ?-lactamaseInfo
- Publication number
- MA38227A1 MA38227A1 MA38227A MA38227A MA38227A1 MA 38227 A1 MA38227 A1 MA 38227A1 MA 38227 A MA38227 A MA 38227A MA 38227 A MA38227 A MA 38227A MA 38227 A1 MA38227 A1 MA 38227A1
- Authority
- MA
- Morocco
- Prior art keywords
- lactamase
- inhibitors
- antibacterial agents
- bicyclic compounds
- novel bicyclic
- Prior art date
Links
- 239000003242 anti bacterial agent Substances 0.000 title 1
- 125000002619 bicyclic group Chemical group 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 150000001768 cations Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Emergency Medicine (AREA)
Abstract
L'invention concerne un composé de formule (i), dans laquelle m est hydrogène ou un cation formant un sel pharmaceutiquement acceptable; y est or1 ou nr2r3, et r1, r2, r3 et m sont tels que définis ici. L'invention concerne également des méthodes de traitement d'une infection bactérienne, des compositions pharmaceutiques, des complexes moléculaires et des procédés pour la préparation des composés.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2012/002675 WO2014091268A1 (fr) | 2012-12-11 | 2012-12-11 | Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de β-lactamase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA38227A1 true MA38227A1 (fr) | 2016-12-30 |
| MA38227B1 MA38227B1 (fr) | 2017-10-31 |
Family
ID=50933808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38227A MA38227B1 (fr) | 2012-12-11 | 2012-12-11 | Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ß-lactamase |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP2931723B1 (fr) |
| JP (1) | JP2016503000A (fr) |
| KR (1) | KR20150093809A (fr) |
| CN (1) | CN105873930B (fr) |
| AU (1) | AU2012396338B2 (fr) |
| BR (1) | BR112015013450A8 (fr) |
| CA (1) | CA2893804C (fr) |
| CR (1) | CR20150359A (fr) |
| EA (1) | EA028633B1 (fr) |
| EC (1) | ECSP15029636A (fr) |
| ES (1) | ES2817785T3 (fr) |
| IL (1) | IL239116B (fr) |
| MA (1) | MA38227B1 (fr) |
| MX (1) | MX2015007406A (fr) |
| PH (1) | PH12015501303A1 (fr) |
| SG (1) | SG11201504540TA (fr) |
| UA (1) | UA111925C2 (fr) |
| WO (1) | WO2014091268A1 (fr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE046893T2 (hu) * | 2012-05-30 | 2020-04-28 | Meiji Seika Pharma Co Ltd | Új ß-laktamáz inhibitor és eljárás elõállítására |
| IN2014MU00194A (fr) * | 2014-01-21 | 2015-08-28 | Wockhardt Ltd | |
| CN105801579A (zh) * | 2014-12-31 | 2016-07-27 | 卢来春 | 一种β-内酰胺酶抑制剂 |
| WO2016120752A1 (fr) * | 2015-01-28 | 2016-08-04 | Wockhardt Limited | Procédé de préparation de (2s, 5r)-n-(2-aminoéthoxy)-6-(sulfooxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide |
| WO2017002087A1 (fr) * | 2015-07-02 | 2017-01-05 | Wockhardtlimited | Composés bicycliques contenant de l'azote et leur utilisation dans le traitement d'infections bactériennes |
| CA2984024A1 (fr) | 2015-09-16 | 2017-03-23 | Xuanzhu Pharma Co., Ltd. | Inhibiteurs de beta-lactase et utilisations associees |
| CN108137567A (zh) | 2015-10-02 | 2018-06-08 | 乐高化学生物科学股份有限公司 | 用于抑制β-内酰胺酶的组合物和方法 |
| WO2017081615A1 (fr) * | 2015-11-09 | 2017-05-18 | Wockhardt Limited | 7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1] octane contenant des composés et leur utilisation dans le traitement d'infections bactériennes |
| CN108602822A (zh) * | 2015-12-11 | 2018-09-28 | 沃克哈特有限公司 | 含有7-氧代-6-(硫氧基)-1,6-二氮杂双环[3.2.1]辛烷-2-甲酰胺的化合物及其在治疗细菌感染中的用途 |
| SI3464336T1 (sl) | 2016-06-01 | 2022-06-30 | Athira Pharma, Inc. | Spojine |
| WO2017206948A1 (fr) * | 2016-06-03 | 2017-12-07 | 南京明德新药研发股份有限公司 | Nouveau diazabicyclo b-lactamase inhibiteurs |
| MY193239A (en) * | 2016-06-03 | 2022-09-27 | Qilu Pharmaceutical Co Ltd | Novel b-lactamase inhibitors |
| WO2017216764A1 (fr) * | 2016-06-17 | 2017-12-21 | Wockhardt Limited | Dérivés de n-(alcanoyl)-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-2-carbonylhydrazide et leur utilisation comme agents antibactériens |
| WO2017216763A1 (fr) * | 2016-06-17 | 2017-12-21 | Wockhardt Limited | Dérivés de n-phénylalcoxy-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-2-carboxamide et leur utilisation en tant qu'agents antibactériens |
| KR102354697B1 (ko) * | 2017-03-02 | 2022-01-21 | 욱크하르트 리미티드 | 항박테리아 화합물로서의 헤테로고리 유도체 |
| CN106831772B (zh) * | 2017-03-04 | 2019-12-17 | 丽珠医药集团股份有限公司 | 一种阿维巴坦中间体的合成方法 |
| WO2018203194A1 (fr) * | 2017-05-02 | 2018-11-08 | Wockhardt Limited | Dérivés de diazabicyclooctane comprenant un groupe d'ammonium quaternaire destiné à être utilisé en tant qu'agents antibactériens |
| WO2018203197A1 (fr) * | 2017-05-02 | 2018-11-08 | Wockhardt Limited | Dérivés de diazabicyclooctane comprenant un groupe oxyimino destiné à être utilisé en tant qu'agents antibactériens |
| CN107383034A (zh) * | 2017-06-29 | 2017-11-24 | 上海药明康德新药开发有限公司 | 外消旋‑5‑(叔丁氧羰基)‑八氢呋喃并[3,2‑c]吡啶‑3a‑羧酸的合成方法 |
| KR20200030584A (ko) | 2017-07-21 | 2020-03-20 | 앤타바이오 에스에이에스 | 화합물 |
| KR20200091395A (ko) * | 2017-09-27 | 2020-07-30 | 페도라 파마슈티칼스 인코포레이티드 | 디아자비시클로옥탄 유도체의 결정형 및 그의 제조 방법 |
| US11180501B2 (en) | 2017-12-01 | 2021-11-23 | Qilu Pharmaceutical Co., Ltd. | Crystal form of β-lactamase inhibitor and preparation method therefor |
| EP3572411A1 (fr) | 2018-05-21 | 2019-11-27 | Antabio SAS | Dérivés de thiazole comme inhibiteurs de métallo-bêta-lactamases |
| EP3608318A1 (fr) * | 2018-08-09 | 2020-02-12 | Antabio SAS | Derives de diaazabicyclooctanone comme antibiotiques |
| EP4272831A3 (fr) * | 2018-08-09 | 2024-02-21 | Antabio SAS | Diazabicyclooctanones comme inhibiteurs de sérine beta-lactamases |
| US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
| CN113292499B (zh) * | 2020-02-24 | 2024-05-28 | 齐鲁制药有限公司 | 一种β-内酰胺酶抑制剂的新制备方法及其中间体 |
| CN117384169B (zh) * | 2022-07-05 | 2025-10-17 | 福安药业集团重庆三禾兴医药科技有限公司 | 一类噻唑胺-二氮杂双环辛酮缀合衍生物及其用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4337197A (en) | 1980-10-31 | 1982-06-29 | E. R. Squibb & Sons, Inc. | O-sulfated β-lactam hydroxamic acids and intermediates |
| FR2812635B1 (fr) | 2000-08-01 | 2002-10-11 | Aventis Pharma Sa | Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens |
| FR2825705B1 (fr) | 2001-06-08 | 2005-05-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens |
| FR2835186B1 (fr) | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases |
| FR2844273B1 (fr) | 2002-09-05 | 2008-04-04 | Aventis Pharma Sa | Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens. |
| US7439253B2 (en) | 2002-12-06 | 2008-10-21 | Novexel | Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors |
| FR2848210B1 (fr) | 2002-12-06 | 2007-10-19 | Aventis Pharma Sa | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases |
| US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| CA2672327A1 (fr) | 2006-11-30 | 2008-06-05 | Genentech, Inc. | Composes azaindolyliques et procedes d'utilisation de ceux-ci |
| FR2914923B1 (fr) | 2007-04-12 | 2013-06-14 | Novexel | Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens. |
| FR2921060B1 (fr) | 2007-09-14 | 2012-06-15 | Novexel | Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires |
| JP5038509B2 (ja) * | 2008-01-18 | 2012-10-03 | メルク・シャープ・エンド・ドーム・コーポレイション | β−ラクタマーゼ阻害剤 |
| FR2936951B1 (fr) | 2008-10-10 | 2010-12-03 | Novexel | Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments |
| WO2010126820A2 (fr) | 2009-04-30 | 2010-11-04 | Merck Sharp & Dohme Corp. | Préparation d'esters alkyliques d'acides oxo-azacycloalkylcarboxyliques n-protégés |
| US8772490B2 (en) | 2010-12-22 | 2014-07-08 | Meiji Seika Pharma Co., Ltd. | Optically active diazabicyclooctane derivatives and process for preparing the same |
| US8829191B2 (en) * | 2011-06-17 | 2014-09-09 | Melanie Simone Ronsheim | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
| BR112013028813B1 (pt) * | 2011-08-27 | 2020-10-20 | Wockhardt Limited | derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e composições farmacêuticas que os compreendem |
| HUE046893T2 (hu) * | 2012-05-30 | 2020-04-28 | Meiji Seika Pharma Co Ltd | Új ß-laktamáz inhibitor és eljárás elõállítására |
| ES2672100T3 (es) * | 2012-08-25 | 2018-06-12 | Wockhardt Limited | Derivados de 1,6-diazabiciclo[3,2,1]octano-7-ona y su uso en el tratamiento de infecciones bacterianas |
-
2012
- 2012-11-12 UA UAA201506795A patent/UA111925C2/uk unknown
- 2012-12-11 CA CA2893804A patent/CA2893804C/fr not_active Expired - Fee Related
- 2012-12-11 EA EA201500544A patent/EA028633B1/ru not_active IP Right Cessation
- 2012-12-11 KR KR1020157018433A patent/KR20150093809A/ko not_active Ceased
- 2012-12-11 MA MA38227A patent/MA38227B1/fr unknown
- 2012-12-11 ES ES12889814T patent/ES2817785T3/es active Active
- 2012-12-11 JP JP2015547152A patent/JP2016503000A/ja active Pending
- 2012-12-11 BR BR112015013450A patent/BR112015013450A8/pt not_active Application Discontinuation
- 2012-12-11 MX MX2015007406A patent/MX2015007406A/es unknown
- 2012-12-11 WO PCT/IB2012/002675 patent/WO2014091268A1/fr not_active Ceased
- 2012-12-11 CN CN201280078211.6A patent/CN105873930B/zh not_active Expired - Fee Related
- 2012-12-11 SG SG11201504540TA patent/SG11201504540TA/en unknown
- 2012-12-11 EP EP12889814.5A patent/EP2931723B1/fr active Active
- 2012-12-11 AU AU2012396338A patent/AU2012396338B2/en not_active Ceased
-
2015
- 2015-06-01 IL IL239116A patent/IL239116B/en active IP Right Grant
- 2015-06-08 PH PH12015501303A patent/PH12015501303A1/en unknown
- 2015-07-08 CR CR20150359A patent/CR20150359A/es unknown
- 2015-07-10 EC ECIEPI201529636A patent/ECSP15029636A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014091268A1 (fr) | 2014-06-19 |
| UA111925C2 (uk) | 2016-06-24 |
| EP2931723A4 (fr) | 2016-06-01 |
| PH12015501303A1 (en) | 2015-08-24 |
| EA201500544A1 (ru) | 2015-12-30 |
| IL239116A0 (en) | 2015-07-30 |
| NZ709355A (en) | 2017-09-29 |
| EP2931723A1 (fr) | 2015-10-21 |
| CA2893804C (fr) | 2021-05-18 |
| ECSP15029636A (es) | 2016-01-29 |
| CA2893804A1 (fr) | 2014-06-19 |
| EP2931723B1 (fr) | 2020-08-26 |
| CN105873930B (zh) | 2019-02-19 |
| AU2012396338B2 (en) | 2017-09-28 |
| IL239116B (en) | 2019-05-30 |
| BR112015013450A8 (pt) | 2019-10-08 |
| AU2012396338A1 (en) | 2015-07-16 |
| JP2016503000A (ja) | 2016-02-01 |
| CN105873930A (zh) | 2016-08-17 |
| MX2015007406A (es) | 2015-12-03 |
| SG11201504540TA (en) | 2015-07-30 |
| KR20150093809A (ko) | 2015-08-18 |
| CR20150359A (es) | 2015-08-20 |
| MA38227B1 (fr) | 2017-10-31 |
| BR112015013450A2 (pt) | 2017-07-11 |
| ES2817785T3 (es) | 2021-04-08 |
| EA028633B1 (ru) | 2017-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA38227B1 (fr) | Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ß-lactamase | |
| MA35128B1 (fr) | Nouveaux dérivés d'imidazole utiles pour le traitement de l'arthrite | |
| MA35826B1 (fr) | Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk | |
| MA58181B1 (fr) | Composés tricycliques substitués | |
| MA35576B1 (fr) | Nouveaux composés | |
| TN2014000147A1 (fr) | Derives de (4-phenylimidazol-2-yl) ethylamine utiles comme modulateurs de canal sodique | |
| MA50391B1 (fr) | Composés d' imidazo[4,5-b]pyridine et compositions pharmaceutiques les contenant destinés à traiter les troubles inflammatoires | |
| MA42295B1 (fr) | Composés de la benzoxazépin oxazolidinone et procédé pour leur utilisation | |
| MA37929A1 (fr) | Composés bis(fluoroalkyl) -1,4-benzodiazépinones en tant qu'inhibiteurs de notch | |
| MA34727B1 (fr) | Imidazolylimidazoles condensés utilisés comme composés antiviraux | |
| MA37866B1 (fr) | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur | |
| WO2019007696A1 (fr) | Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose | |
| MA37762A1 (fr) | Composés n-aryltriazole utilisés comme antagonistes de lpar | |
| MA42231B1 (fr) | Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant | |
| MA37764A1 (fr) | Composés n-alkyltriazole utilisés comme antagonistes de lpar | |
| MA35725B1 (fr) | Composés pipérazines alkylés en tant qu'inhibiteurs de l'activité btk | |
| MA34308B1 (fr) | Triazolopyridines substituées | |
| MA41134A (fr) | Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales | |
| MA37888B1 (fr) | Composition pharmaceutique enrobée contenant du régorafenib | |
| MA35601B1 (fr) | Pyrrolotriazines substituées par hydroxyméthylaryle utilisées comme inhibiteurs d'alk1 | |
| MA38661A1 (fr) | Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine | |
| MA37891A1 (fr) | Alcoxypyrazoles comme activateurs de guanylate cyclase soluble | |
| MA35444B1 (fr) | Ligands du récepteur ep1 | |
| MA38333A1 (fr) | Composés d'azabenzimidazole en tant qu'inhibiteurs d'isozymes pde4 pour le traitement de troubles du snc et d'autres affections | |
| MA34331B1 (fr) | Composés pyrazole comme inhibiteurs du récepteur sigma |